Business
BIOCARDIA ANNOUNCES TIMING FOR PRESPECIFIED DATA SAFETY MONITORING BOARD REPORT ON PIVOTAL CARDIAMP HEART FAILURE TRIAL
Company to Host a Conference Call with National Co-Principal Investigators on March 31, 2020 at 4:15 p.m. ET Fourth Quarter 2019 Financial Results to be
About this update from Biocardia, Inc.
[{"type":"text","content":"Company to Host a Conference Call with National Co-Principal Investigators on March 31, 2020 at 4:15 p.m. ET\n Fourth Quarter 2019 Financial Results to be Issued March 30, 2020 SAN CARLOS, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) is expected to report on a prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which will be available for release on Tuesday, March 31, 2020. The report will be based on a review of all available safety data from all patients randomized in the trial. To date, 72 patients have been enrolled in the trial. BioCardia will host a conference call/webcast to provide updates on the CardiAMP Heart Failure Trial featuring national co-principal investigators, Amish Raval, MD, of the University of Wisconsin and Carl Pepine, MD, of the University of Florida, Gainesville, on Tuesday, March 31 at 4:15 p.m. ET. To participate in this conference call, dial 1-877-270-2148. To access a live webcast of the call, please visit: www.biocardia.com/investors/events-presentations/id/1036. A replay of the webcast will be available for a limited time on the BioCardia website following the presentation. The ongoing multi-center, double-blinded, randomized (3:2), sham-controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide. The trial’s primary efficacy endpoint is a composite of Six Minute Walk distance at 12 months’ post-treatment (a measure of a patient’s exercise capacity), which incorporates the impact of Major Adverse Cardiac Events (MACE) and other clinically meaningful events. Secondary efficacy endpoints include quality of life as measured by the Minnesota Heart Failure Quality of Life self-assessment, and superiority relative to MACE and survival. The company will be reporting fourth quarter 2019 financial results on the prior day, Monday, March 30. About the CardiAMP Therapy ProgramCardiAMP cell therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally-invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The CardiAMP Heart Failure Trial is the first multi-cen...